Linperlisib

林普利塞

Report date: 2025/05/22 15:16:31
NME

Base Information

Drug NameLinperlisib
Drug Alias Name林普利司因他瑞IntarelYY-20394HRS-3536
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsSolid tumoursAnemia, Hemolytic, AutoimmuneThymus Neoplasms +[17] 
Global Approved IndicationsLymphoma, Follicular
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryMainland China
Original Approved Date2022/11/08
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYL-Pharma
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPeking UniversityThe University Of Texas MD Anderson Cancer CenterSun Yat-Sen University +[6] 
Inactive CompaniesJiangsu Hengrui Medicine Co Ltd
Active IndicationsSolid tumoursThymus NeoplasmsHematologic Neoplasms +[14] 
Inactive IndicationsAnemia, Hemolytic, AutoimmuneLymphoma, B-CellLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A